ArticleFrontiers in medicine2025
Association of antenatal dexamethasone administration timing with outcomes in preterm infants in a low- and middle-income country.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Timely administration of antenatal corticosteroids improves preterm outcomes; however, in low- and middle-income countries (LMICs), multiple barriers often delay treatment. Whether exposure within 24 h before delivery confers benefits remains uncertain. We aimed to evaluate the association between antenatal dexamethasone-to-delivery intervals and preterm outcomes in an LMIC setting. Methods: This single-center prospective cohort study was conducted at a tertiary neonatal intensive care unit in India from June 2023 to December 2024. The participants were preterm infants born at 24 0/7-33 6/7 week gestation. Exclusion criteria were major congenital anomalies, multiple courses of dexamethasone, administration-to-birth interval > 7 d, and interfacility transfer. The exposure variable was maternal first dexamethasone dose-to-delivery interval, categorized as ≤ 24 h ( Results: Of the 371 infants born during the study period, 332 met eligibility criteria (mean gestational age, 30.6 ± 2.2 week; 60.5% male). Overall mortality was 7.8% (26/332): 11.9% (12/101) without dexamethasone, 6.6% (11/167) with ≤ 24 h exposure, and 4.7% (3/64) with > 24 h-7 d exposure. Mortality did not differ by dexamethasone timing intervalgroup: ≤ 24 h (aRR, 0.58; 95%CI 0.26-1.27) and > 24 h-7 d (aRR, 0.33; 95%CI, 0.10-1.12) vs. no dexamethasone. Wide CIs were observed, reflecting imprecision due to lower-than-expected mortality in the unexposed group. Severe NEC was lower with ≤ 24 h exposure (1.8% [3/167] vs. 8.9% [9/101]; aRR, 0.15; 95%CI 0.04-0.54), persisting in sensitivity analyses (aRR, 0.11; 95%CI 0.03-0.38) and after multiple-comparison adjustment. No other secondary outcomes differed significantly. Conclusion: Dexamethasone administration within 24 h before delivery did not reduce mortality but significantly decreased the risk of severe NEC. Imprecise estimates due to lower-than-expected mortality, reduced statistical power, and potential residual confounding limit definitive conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.